Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Go back to Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
(NASDAQ: EVAX) Delayed: 3.30 -0.08 (2.37%)
Previous Close $3.38    52 Week High
Open $3.37    52 Week Low
Day High $3.37    P/E N/A 
Day Low $3.30    EPS
Volume 7,777